01:06 PM EDT, 04/09/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) , a clinical-stage biotechnology company, is presenting positive clinical data from its lead product candidate, Bria-IMT, in two of its three poster sessions during the 2024 American Association for Cancer Research (AACR) Annual Meeting held from April 5-10 in San Diego, CA.

"The clinical data further validates Bria-IMT's novel mechanism of action to generate immune responses in breast cancer patients who failed ADCs (antibody-drug conjugates), leading to clinically relevant survival and treatment benefit in these patients," said Dr. Giuseppe Del Priore, BriaCell's chief medical officer. "We look forward to building upon the body of evidence with additional clinical data in the coming months from the ongoing pivotal registration trial."

According to lead author Chaitali Nangia, MD, Partner at Hoag Medical Group, ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer. However, some patients experience resistance with rapid disease progression.

BriaCell shares were last seen down C$0.08 to C$3.87 on the Toronto Stock Exchange.

Price: 3.87, Change: -0.08, Percent Change: -2.03